NASDAQ:PSNL Personalis - PSNL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.90 +0.86 (+28.29%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.93▼$4.2550-Day Range$1.78▼$3.9052-Week Range$1.73▼$12.96Volume7.85 million shsAverage Volume316,641 shsMarket Capitalization$179.28 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Personalis MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside233.3% Upside$13.00 Price TargetShort InterestBearish4.68% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.20Based on 3 Articles This WeekInsider TradingSelling Shares$48,910 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.46) to ($2.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector211th out of 1,028 stocksMedical Laboratories Industry6th out of 25 stocks 3.4 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Personalis has a forecasted upside of 233.3% from its current price of $3.90.Amount of Analyst CoveragePersonalis has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.68% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Personalis has recently increased by 32.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePersonalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Personalis is -0.66. Previous Next 2.3 News and Social Media Coverage News SentimentPersonalis has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Personalis this week, compared to 2 articles on an average week.Search Interest9 people have searched for PSNL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,910.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of Personalis is held by insiders.Percentage Held by Institutions60.84% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($2.46) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Personalis (NASDAQ:PSNL) StockPersonalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.Read More Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address PSNL Stock News HeadlinesFebruary 4, 2023 | finance.yahoo.comWhy Personalis Shares Are Trading Higher TodayJanuary 27, 2023 | finance.yahoo.comCancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its WorkforceFebruary 4, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 5, 2023 | marketwatch.comPersonalis Shares Up 5.5% After Hours on Preliminary 4Q Revenue BoostJanuary 4, 2023 | finance.yahoo.comPersonalis Reports Preliminary Fourth Quarter and Full Year 2022 RevenueDecember 14, 2022 | finance.yahoo.comPersonalis Announces CEO Retirement and TransitionNovember 30, 2022 | finance.yahoo.comPersonalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal CancerNovember 21, 2022 | finance.yahoo.comPersonalis to Present at the 34th Annual Piper Sandler Healthcare ConferenceFebruary 4, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…November 7, 2022 | finance.yahoo.comHere's Why Personalis (NASDAQ:PSNL) Must Use Its Cash WiselyNovember 7, 2022 | finance.yahoo.comPersonalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNovember 2, 2022 | finance.yahoo.comPersonalis (PSNL) Reports Q3 Loss, Misses Revenue EstimatesNovember 2, 2022 | finance.yahoo.comPersonalis Reports Third Quarter 2022 Financial ResultsNovember 1, 2022 | finance.yahoo.comPersonalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics BusinessOctober 19, 2022 | finance.yahoo.comPersonalis to Announce Third Quarter 2022 Financial ResultsOctober 17, 2022 | seekingalpha.comAmbrx, MorphoSys top healthcare gainers; NGM, Minerva lead losers' pack - Seeking AlphaOctober 12, 2022 | au.finance.yahoo.comPersonalis, Inc.'s (NASDAQ:PSNL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance AustraliaOctober 11, 2022 | finance.yahoo.comPersonalis, Inc.'s (NASDAQ:PSNL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measuresOctober 4, 2022 | businesswire.comPersonalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer - Business WireOctober 4, 2022 | finance.yahoo.comPersonalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal CancerSeptember 28, 2022 | nasdaq.comInsiders are probably glad they sold their shares in Personalis, Inc. (NASDAQ:PSNL) after 13% dropSeptember 26, 2022 | nasdaq.comInsiders are probably glad they sold their shares in Personalis, Inc. (NASDAQ:PSNL) after 13% drop - NasdaqSeptember 1, 2022 | businesswire.comGlobal Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2022: Increasing Prevalence of Cancer Worldwide and the Rise in Awareness of Advanced Treatment of Cancer Driving Growth - ResearchAndMarkets.com - Business WireAugust 30, 2022 | finance.yahoo.comPersonalis to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 21, 2022 | fool.comPersonalis, Inc. (NASDAQ: PSNL)August 17, 2022 | finance.yahoo.comPersonalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight DiagnosticsAugust 8, 2022 | finance.yahoo.comIs Personalis (NASDAQ:PSNL) Using Debt Sensibly?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address PSNL Company Calendar Last Earnings11/04/2021Today2/04/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PSNL CUSIPN/A CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees325Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+233.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,230,000.00 Net Margins-148.46% Pretax Margin-148.41% Return on Equity-37.12% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio6.58 Quick Ratio6.35 Sales & Book Value Annual Sales$85.49 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book0.56Miscellaneous Outstanding Shares45,970,000Free Float42,523,000Market Cap$179.28 million OptionableNot Optionable Beta1.53 Key ExecutivesAaron TachibanaChief Executive OfficerChristopher M. HallPresidentRichard O. ChenChief Medical Officer, SVP-Research & DevelopmentXavier PaliardVice President-Immunology, Research & DevelopmentStephen M. MooreSecretary, Vice President & General CounselKey CompetitorsMDxHealthNASDAQ:MDXHGenetronNASDAQ:GTHBiodesixNASDAQ:BDSXCelcuityNASDAQ:CELCAkuminNASDAQ:AKUView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 6,300 shares on 2/2/2023Ownership: 0.000%Bank of Montreal CanBought 139,800 shares on 2/1/2023Ownership: 0.304%Aaron TachibanaSold 767 sharesTotal: $1,687.40 ($2.20/share)Richard ChenSold 562 sharesTotal: $1,236.40 ($2.20/share)Sumitomo Mitsui Trust Holdings Inc.Sold 60,231 shares on 1/30/2023Ownership: 1.936%View All Insider TransactionsView All Institutional Transactions PSNL Stock - Frequently Asked Questions Should I buy or sell Personalis stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSNL shares. View PSNL analyst ratings or view top-rated stocks. What is Personalis' stock price forecast for 2023? 4 analysts have issued 1-year price objectives for Personalis' stock. Their PSNL share price forecasts range from $6.00 to $24.00. On average, they predict the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts. How have PSNL shares performed in 2023? Personalis' stock was trading at $1.98 at the start of the year. Since then, PSNL shares have increased by 97.0% and is now trading at $3.90. View the best growth stocks for 2023 here. Are investors shorting Personalis? Personalis saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,700,000 shares, an increase of 32.8% from the December 31st total of 1,280,000 shares. Based on an average daily volume of 379,000 shares, the short-interest ratio is presently 4.5 days. Currently, 4.7% of the company's shares are short sold. View Personalis' Short Interest. When is Personalis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our PSNL earnings forecast. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). The business had revenue of $22.26 million for the quarter, compared to analyst estimates of $22.20 million. Personalis had a negative net margin of 148.46% and a negative trailing twelve-month return on equity of 37.12%. During the same quarter in the prior year, the firm posted ($0.27) EPS. What guidance has Personalis issued on next quarter's earnings? Personalis updated its fourth quarter 2022 earnings guidance on Wednesday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $16.70 million-$16.70 million, compared to the consensus revenue estimate of $15.33 million. What is John West's approval rating as Personalis' CEO? 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and When did Personalis IPO? (PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager. What is Personalis' stock symbol? Personalis trades on the NASDAQ under the ticker symbol "PSNL." Who are Personalis' major shareholders? Personalis' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.96%), Sumitomo Mitsui Trust Holdings Inc. (1.94%), Bank of Montreal Can (0.30%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Aaron Tachibana, John Stephen West, Ken Ludlum, Lightspeed Venture Partners Se, Llp Abingworth, Richard Chen and Stephen Michael Moore. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Personalis' stock price today? One share of PSNL stock can currently be purchased for approximately $3.90. How much money does Personalis make? Personalis (NASDAQ:PSNL) has a market capitalization of $179.28 million and generates $85.49 million in revenue each year. The company earns $-65,230,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. How many employees does Personalis have? The company employs 325 workers across the globe. How can I contact Personalis? Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.personalis.com. The company can be reached via phone at (650) 752-1300 or via email at investors@personalis.com. This page (NASDAQ:PSNL) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.